<DOC>
	<DOCNO>NCT02753647</DOCNO>
	<brief_summary>This prospective , single-arm , open-label phase II study Chidamide combination R-CHOP treatment de novo , elderly , high-risk diffuse large B cell lymphoma patient .</brief_summary>
	<brief_title>Chidamide Plus R-CHOP Elderly DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Pathologically confirm diffuse large Bcell lymphoma , CD20 positive Age 6175 year ECOG 0,1,2 Life expectancy &gt; 6 month Informed consented IPI &gt; 1 Chemotherapy Stem cell transplantation History malignancy except basal cell squamous cell carcinoma skin carcinoma situ cervix Uncontrollable cardiocerebral vascular , coagulative , autoimmune , serious infectious disease Primary CNS lymphoma LVEFâ‰¤50 % Lab enrollment ( Unless cause lymphoma ) Neutrophile &lt; 1.5*10^9/L Platelet &lt; 75*10^9/L ALT AST &gt; 2*ULN , AKP bilirubin &gt; 1.5*ULN Creatinine &gt; 1.5*ULN Other uncontrollable medical condition may may interfere participation study Not able comply protocol mental unknown reason Pregnant lactation HIV infection If HbsAg positive , check HBV DNA , DNA positive patient enrol . If HBsAg negative HBcAb positive ( whatever HBsAb status ) , check HBV DNA , DNA positive patient enrol .</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>